Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education.
Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.
Expert faculty review the use of targeted oral therapies for HR+/HER2- breast cancer.
Resources for your patients: https://www.smartpatients.com/resources/cco-breast-cancer
Dr Yara Abdou discusses BRCA mutation testing and adjuvant therapy with olaparib in BRCA-mutated, HER2-negative early breast cancer, from Clinical Care Options (CCO)
Slideset from Dr Yara Abdou on adjuvant olaparib in BRCA1/2-mutated, HER2-negative early breast cancer, from Clinical Care Options (CCO)
Dr. Yara Abdou discusses Ki-67 testing and adjuvant abemaciclib in HR+/HER2-, node-positive, high-risk early breast cancer, from Clinical Care Options (CCO)
Slideset from Dr. Yara Abdou on Ki-67 and adjuvant abemaciclib for HR+/HER2-, node-positive, high-risk EBC, from Clinical Care Options (CCO)
For further information concerning Lilly grant funding,